Elicio Therapeutics, Inc. · NASDAQ:ELTX

Elicio Therapeutics — Technical Presentation (June 2026)

23 slides from Elicio Therapeutics's technical presentation, Jun 24, 2026

  1. Slide 1: AMPLIFY-7P: Defining the Path Forward for ELI-002 7P in Metastatic mKRAS PDAC

    AMPLIFY-7P Defining the Path Forward for ELI-002 7P in Metastatic mKRAS PDAC JUNE 24, 2026

  2. Slide 2: Disclaimers

    Disclaimers No Representation or Warranty We do not make and hereby expressly disclaim any representation or warranty, express or implied, as to the reasonableness of the assumptions made in the Presentation or the accuracy or completeness or the information contained in or incorporated by reference

  3. Slide 3: Speaker Agenda

    SpeakerAgenda Christopher Haqq, M.D., Ph.D., Executive Vice President, Head of Research and Development and Chief Medical OfficerIntroduction01 Zev Wainberg, M.D., Professor of Medicine, UCLA, Co-Director of the UCLA GI Oncology ProgramReview of Historical mPDAC Studies02 Peter Hosein, M.D., Profess

  4. Slide 4: Christopher Haqq, M.D., Ph.D. - Introduction

    Christopher Haqq, M.D., Ph.D., Executive Vice President, Head of Research and Development and Chief Medical Officer

  5. Slide 5: Multiple Confirmed Complete Responses Observed Following ELI-002 7P Treatment, Subsequent Therapy in metastatic PDAC

    Multiple Confirmed Complete Responses Observed Following ELI-002 7P Treatment, Subsequent Therapy in metastatic PDAC 5 Hypothesis: ELI-002 7P primes mKRAS-specific immunity to enhance responsiveness to subsequent treatment Elicio believes these observations provide preliminary clinical support for e

  6. Slide 6: Zev Wainberg, M.D., Professor of Medicine, UCLA

    Zev Wainberg, M.D., Professor of Medicine, UCLA, Co-Director of the UCLA GI Oncology Program

  7. Slide 7: Complete Responses Remain Rare in Metastatic Pancreatic Cancer Across Therapeutic Modalities

    Complete Responses Remain Rare in Metastatic Pancreatic Cancer Across Therapeutic Modalities 7 | Elicio Therapeutics Published studies evaluating chemotherapy, checkpoint inhibitors, and targeted therapies generally report complete response rates ranging from 0–8% CR signalPopulationRegimen / Study

  8. Slide 8: Immunotherapy with Chemotherapy or Radiation Has Not Been Effective

    Immunotherapy with Chemotherapy or Radiation Has Not Been Effective 8 | Elicio Therapeutics Historical rates of complete response: 2-6% for Nivo + GnP, 0% for Nivo + SBRT CR SignalPopulationRegimen / Study 2% (1 / 50) 1First Line (1L) mPDACNivo + GnP (PRINCE) 3% (1 / 34) 2First Line (1L) mPDACNivo +

  9. Slide 9: Peter Hosein, M.D., Professor of Clinical Medicine, University of Miami

    Peter Hosein, M.D., Professor of Clinical Medicine, Sylvester Comprehensive Cancer Center, University of Miami

  10. Slide 10: Complete Responses Observed Following ELI-002 7P and Subsequent Checkpoint Inhibition

    10 Three patients who recurred following ELI-002 7P treatment subsequently achieved complete radiographic response, complete metabolic response, and biomarker normalization after nivolumab-based therapy These observations provide preliminary clinical support for evaluating ELI-002 7P in combination

  11. Slide 11: Complete Responses Were Confirmed and Durable

    11 [1] June 21, 2026; GnP: Gemcitabine Nab-paclitaxel; CR: Complete Response; PR: Partial Response; PD: Progressive Disease; SBRT: Stereotactic Body Radiation Therapy; NED: No evidence of disease; PFS: Progression-free survival; DOR: Duration of response Current StatusDOR 1Nivo start → PR / CR Tumor

  12. Slide 12: Patient 1: Complete Response Following ELI-002 7P and Subsequent Nivolumab

    12 GnP: Gemcitabine Nab-paclitaxel; PFS: Progression-free survival; DOR: Duration of response; CT: Computed tomography; PET: Positron emission tomography; SUVmax: Standardized uptake value RECIST: Complete Response (CR) PERCIST: Complete Metabolic Response (CMR) Complete Radiographic, Metabolic, and

  13. Slide 13: Patient 2: Complete Response Following ELI-002 7P and Subsequent Nivolumab

    13 Complete Radiographic, Metabolic, and Biomarker Resolution of Gastro-hepatic Ligament Nodes Week 28: SUVmax 8.0 Week 69: SUVmax background Patient 2: CA19-9 Tumor Biomarker Values, Treatment Timeline Patient 2: PET / CT Week 28 PET / CT Week 69 PET / CT Gastro-hepatic Ligament Node CA 19 -9 (U /m

  14. Slide 14: Patient 3: Complete Response Following ELI-002 7P and Subsequent Nivolumab

    14 Complete Metabolic, and Biomarker Resolution of Mesenteric Local Recurrence CA 19 -9 (U /m L) Week 35: SUVmax 8.6 Week 48: SUVmax background Patient 3: CA19-9 Tumor Biomarker Values, Treatment Timeline Patient 3: PET / CT Week 35 PET / CT Week 48 PET / CT Mesenteric Local Recurrence 0 10 20 30 40

  15. Slide 15: Multiple Confirmed Complete Responses Warranting Further Evaluation

    15 MSS: Micro-satellite stable; MMR: Mismatch Repair Multiple Confirmed Complete Responses Observed Following ELI-002 7P Treatment and Subsequent Therapy in metastatic PDAC Warranting Further Evaluation Complete responses following ELI-002 7P treatment and subsequent nivolumab-based therapy warrant

  16. Slide 16: Hypothesized Mechanism for Complete Responses Following ELI-002 7P and Subsequent Therapy

    Hypothesized Mechanism for Complete Responses Following ELI-002 7P and Subsequent Therapy 16 Observations from presented patients suggest a hypothetical mechanism for anti-tumor T cell responses and tumor modulation following ELI-002 7P treatment and subsequent nivolumab-based therapy. ELI-002 7P ma

  17. Slide 17: T cell Infiltration after ELI-002 7P Preceded Complete Responses

    T cell Infiltration after ELI-002 7P Preceded Complete Responses 17 Observations of increased T cell tumor infiltration, and modulation of tumor PD-L1 following recurrence after ELI-002 7P CD3 CD8 PD-L1 CK (PDAC) H& E M ul tip le x IF Scale: 200 µm Patient 1 Patient 2 H&E: Hematoxylin and eosin; IF:

  18. Slide 18: mKRAS-specific T cell responses persisted through subsequent chemotherapy and nivolumab treatment

    GnP + CPI 2 ELI-002 7PBaselineTimepoint GnP + CPI 2 ELI-002 7PBaselineTimepointGnP + CPI 2 ELI-002 7PBaselineTimepoint IF N a nd /o r G rB S FC / 1x 10 6 P B M C % IL 2+ IF Nγ + a nd /o r T N Fα + a m on g C D 8+ T c el ls IF N a nd /o r G rB S FC / 1x 10 6 P BM C mKRAS-specific T cell responses1 pe

  19. Slide 19: Complete Responses Associated with Personalized T Cell Responses

    Therapy Complete Responses Associated with Personalized T Cell Responses 19 3 / 3 complete responses were associated with modulation of antigen spreading T cell responses Therapy Immunogenic Non-immunogenic % of Assayed Personalized Tumor Antigens 82 18 ELI-002 7P GnP Nivolumab Radiation These findi

  20. Slide 20: Metastatic PDAC Phase Development Strategy

    Metastatic PDAC Phase 1 Development Strategy 20 Plans for a staged development pathway designed to evaluate ELI-002 7P + CPI across metastatic PDAC settings | Elicio Therapeutics →Recurrent metastatic PDAC (CPI combination) Treatment Naïve metastatic PDAC (CPI and/or RASi combinations) Inform Future

  21. Slide 21: Planned Phase Study Evaluating ELI-002 7P with Checkpoint Inhibition in 1L mPDAC

    Planned Phase 1 Study Evaluating ELI-002 7P in Combination with Checkpoint Inhibition in 1L mPDAC 21 Building on complete response observations to identify rapid clinical insights and inform future metastatic and Phase 3 development ELIGIBILITY • Recurrent and treatment-naïve metastatic PDAC • ≥1 of

  22. Slide 22: Next Steps: Advancing Clinical Development of ELI-002 7P in Metastatic PDAC

    Next Steps: Advancing Clinical Development of ELI-002 7P in Metastatic PDAC in Combination with Checkpoint Inhibition and Other Therapies 22 01 02 Finalize Study Design Initiate Phase 1 Study in mPDAC, subject to funding | Elicio Therapeutics 03 Inform future development plans in metastatic PDAC, an

  23. Slide 23: Elicio Therapeutics

    ‘Delicio THERAPE UTICS

Elicio Therapeutics — Technical Presentation (June 2026) on 6ix